Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS

被引：98

作者：

Calabresi, PA

Fields, NS

Maloni, HW

Hanham, A

Carlino, J

Moore, J

Levin, MC

Dhib-Jalbut, S

Tranquill, LR

Austin, H

McFarland, HF

Racke, MK

机构：

[1] Natl Inst Neurol Disorders & Stroke, Neuroimmunol Branch, Bethesda, MD 20892 USA

[2] NIDDKD, NIH, Kidney Dis Sect, Bethesda, MD 20892 USA

[3] Washington Univ, Sch Med, St Louis, MO USA

[4] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA

[5] Celtrix Pharmaceut Inc, Santa Clara, CA USA

来源：

NEUROLOGY | 1998年 / 51卷 / 01期

关键词：

D O I：

10.1212/WNL.51.1.289

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Transforming growth factor (TGF)-beta 2 is a pleiotropic cytokine associated with remissions in multiple sclerosis (MS) and amelioration of allergic encephalomyelitis. We assessed the safety of TGF-beta 2 in an open-label trial of 11 patients with secondary progressive (SP) MS. Five patients had a reversible decline in the glomerular filtration rate. There was no change in expanded disability status scale or MRI lesions during treatment. Systemic TGF-beta 2 may be associated with reversible nephrotoxicity, and further investigation of its therapeutic potential in MS should be performed with caution.

引用

页码：289 / 292

页数：4

共 10 条

[1]

BECK J, 1991, ACTA NEUROL SCAND, V84, P454

[2] HYDRATED CLEARANCE OF GADOLINIUM-DTPA AS A MEASUREMENT OF GLOMERULAR-FILTRATION RATE [J].